EMA opens investigation into India’s GVK Bio over ECG falsifications

By Zachary Brennan contact

- Last updated on GMT

Review finds falsified electrocardiograms by 10 different employees at GVK
Review finds falsified electrocardiograms by 10 different employees at GVK

Related tags: Gvk bio, Clinical trial, Medicine, Contract research organization

At the request of the European Commission, the EMA (European Medicines Agency) announced Friday that it would open a review into findings that GVK Biosciences’ site in Hyderabad, India falsified electrocardiograms in all nine clinical trials evaluated. 

The investigation follows an inspection by the French regulator ANSM​ at the Indian CRO (contract research organization), which raised concerns about study data dating back to July 2008 used to support the marketing authorisation applications of generic medicines.

ANSM sent a letter​ to marketing authorization holders with regard to the use of GVK BIO’s clinical facility in Hyderabad, India. A GVK spokeswoman previously told us that the ANSM inspection involved the use of ECGs.

But Sabine Jülicher, Head of Unit, Medicinal products – authorisations at the EMA, cited a number of ANSM’s findings in a letter to CHMP, including: “falsifications of electrocardiograms were detected in each and every one of the 9 trials inspected by the ANSM​.”

The falsification of these ECGs was performed by at least 10 different individuals. The falsifications took place between at least July 2008 and 2013…the systematic nature of the falsifications of electrocardiograms, the extended period of time during which they took place and the number of members of staff involved highlight critical deficiencies in the quality system in place at GVK Bio's clinic in Hyderabad​,” Jülicher writes.

They also show a lack of GCP training, awareness and understanding of members of GVK Bio staff, a lack of understanding by them of the importance of data integrity and of the possible consequences of their acts, as well as a lack of overview of clinical trial activities by the investigators,” ​she says. “The seriousness of the deficiencies identified and the lack of GCP compliance at GVK Bio's clinic in Hyderabad raise questions as to the acceptability of the clinical part of all other bioequivalence trials performed at that site in support of marketing authorisations applications​.”

EMA Action

The EMA’s Committee for Medicinal Products for Human Use (CHMP) will now review available data to determine which medicines are affected by the inspection findings and issue a recommendation on whether their marketing authorisations should be maintained, varied, suspended or withdrawn across the EU.

GVK spokeswoman Dorothy Paul told us: "This is a natural next step as per referral procedure initiated by EMA as a follow up of ANSM inspection​."

GVK action

EMA requests that GVK respond in writing several questions, including: “Discuss the root cause of this issue affecting the GVK Biosciences-Hyderabad site and provide assurance that these issues​” are confined to the Hyderabad site from July 2008 to present.

In addition, the European regulator calls on GVK to “indicate which measures have been undertaken to investigate if this is a corporate issue.​”

As far as a timeline, GVK has until Oct. 3 to respond. Between Oct. 13-23, the EMA rapporteur and co-rapporteurs’ assessment reports will be circulated to CHMP, which will offer comments and then update the reports. A list of outstanding issues and CHMP discussion will begin on Oct. 23. 

Related news

Show more

Related products

show more


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Related suppliers